|
Recent Developments |
|
07-FEB-19
Cipla today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Tadalafil Tablets 20mg from the United States Food and Drug Administration (US FDA).
28-JAN-19
Cipla today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Medroxyprogesterone Injectable, 150mg/mL from the United States Food and Drug Administration (US FDA).
12-NOV-18
Cipla to... More.. |
| Business Profile |
Future Plans |
|
|
|
|
One To One
|
|
Recent news
|
|
|
| Period ending (months) | 31-Dec-2017(9) | 31-Mar-2017(12) | 31-Mar-2016(12) | | Net sales | 86403.80 | 107505.10 | 117351.80 | | Other Income | 2720.00 | 1392.10 | 2591.40 | | Total Income | 89123.80 | 108897.20 | 119943.20 | | Cost of goods sold | 69551.00 | 97314.90 | 99803.40 | | OPBDIT | 19572.80 | 11582.30 | 20139.80 | | PAT | 12437.10 | 9750.80 | 13980.30 | | Gross Block | - | - | - | | Equity capital | - | - | 1606.80 | | EPS (Rs.) | - | - | - | | DPS (Rs.) | - | - | - | | BV (Rs.) | - | - | - | | P/E range (x) | - | - | - | | Debt / Equity (x) | - | - | - | | Operating margin (% of OI) | 22.0 | 10.6 | 16.8 | | Net margin (% of OI) | 14.0 | 9.0 | 11.7 |
|
|
Detailed Financials
|
|
|
|
|
